Cargando…
Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation
Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery across the blood–brain barrier (BBB). The gro...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966342/ https://www.ncbi.nlm.nih.gov/pubmed/36839768 http://dx.doi.org/10.3390/pharmaceutics15020443 |
_version_ | 1784896992894255104 |
---|---|
author | Ilić, Tanja Đoković, Jelena B. Nikolić, Ines Mitrović, Jelena R. Pantelić, Ivana Savić, Snežana D. Savić, Miroslav M. |
author_facet | Ilić, Tanja Đoković, Jelena B. Nikolić, Ines Mitrović, Jelena R. Pantelić, Ivana Savić, Snežana D. Savić, Miroslav M. |
author_sort | Ilić, Tanja |
collection | PubMed |
description | Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery across the blood–brain barrier (BBB). The growing availability of innovative excipients/ligands allowing improved brain targeting and controlled drug release makes the lipid nanocarriers a reasonable choice to overcome the factors impeding drug delivery through the BBB. However, a wide variety of methods, study designs and experimental conditions utilized in the literature hinder their systematic comparison, and thus slows the advances in brain-targeting by lipid-based nanoparticles. This review provides an overview of the methods most commonly utilized during the preclinical testing of liposomes, nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers intended for the treatment of various CNS disorders via the parenteral route. In order to fully elucidate the structure, stability, safety profiles, biodistribution, metabolism, pharmacokinetics and immunological effects of such lipid-based nanoparticles, a transdisciplinary approach to preclinical characterization is mandatory, covering a comprehensive set of physical, chemical, in vitro and in vivo biological testing. |
format | Online Article Text |
id | pubmed-9966342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99663422023-02-26 Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation Ilić, Tanja Đoković, Jelena B. Nikolić, Ines Mitrović, Jelena R. Pantelić, Ivana Savić, Snežana D. Savić, Miroslav M. Pharmaceutics Review Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery across the blood–brain barrier (BBB). The growing availability of innovative excipients/ligands allowing improved brain targeting and controlled drug release makes the lipid nanocarriers a reasonable choice to overcome the factors impeding drug delivery through the BBB. However, a wide variety of methods, study designs and experimental conditions utilized in the literature hinder their systematic comparison, and thus slows the advances in brain-targeting by lipid-based nanoparticles. This review provides an overview of the methods most commonly utilized during the preclinical testing of liposomes, nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers intended for the treatment of various CNS disorders via the parenteral route. In order to fully elucidate the structure, stability, safety profiles, biodistribution, metabolism, pharmacokinetics and immunological effects of such lipid-based nanoparticles, a transdisciplinary approach to preclinical characterization is mandatory, covering a comprehensive set of physical, chemical, in vitro and in vivo biological testing. MDPI 2023-01-29 /pmc/articles/PMC9966342/ /pubmed/36839768 http://dx.doi.org/10.3390/pharmaceutics15020443 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ilić, Tanja Đoković, Jelena B. Nikolić, Ines Mitrović, Jelena R. Pantelić, Ivana Savić, Snežana D. Savić, Miroslav M. Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation |
title | Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation |
title_full | Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation |
title_fullStr | Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation |
title_full_unstemmed | Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation |
title_short | Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation |
title_sort | parenteral lipid-based nanoparticles for cns disorders: integrating various facets of preclinical evaluation towards more effective clinical translation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966342/ https://www.ncbi.nlm.nih.gov/pubmed/36839768 http://dx.doi.org/10.3390/pharmaceutics15020443 |
work_keys_str_mv | AT ilictanja parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation AT đokovicjelenab parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation AT nikolicines parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation AT mitrovicjelenar parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation AT pantelicivana parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation AT savicsnezanad parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation AT savicmiroslavm parenterallipidbasednanoparticlesforcnsdisordersintegratingvariousfacetsofpreclinicalevaluationtowardsmoreeffectiveclinicaltranslation |